Compare Medtronic PLC (MDT) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Victoria's Secret & Co — how do they compare? Medtronic PLC trades at $90.72 (market cap $116.07B), while Victoria's Secret & Co trades at $93.88 (market cap $7.48B). The key difference: Medtronic PLC is far larger — about 15.5× Victoria's Secret & Co's market cap, and Medtronic PLC pays a 3.18% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| MDT | VSXY | |
|---|---|---|
Market Cap | $116.07B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $99.97 |
52-Week Low | $73.75 | $21.34 |
Enterprise Value | $134.82B | $10.13B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
VSXY trades at $94.6, down 5.37% today but near its 52-week high, with a bullish technical signal and strong support at $93. The company reported Q1 2026 EPS of $0.60, beating expectations, and shows improving net income margins. Analyst consensus is a Buy with a $91 target, while recent news highlights growth through data-driven marketing and international expansion.
Outlook is positive with earnings momentum and international growth, but risks include high valuation (P/E 37.51) and competitive pressures. Investors may find opportunity in continued execution, though margin sustainability and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
